LAUSR

Mandible osteoporosis with age is characterized by greater fragility and accompanied with abnormal oral function. Mesenchymal stem cell transplantation can ameliorate osteoporosis. Bmi‐1 is a transcriptional repressor which is an important regulator of cell cycle, stem cells self‐renewal, and cell senescence. Here, we use a new kind of membrane mesenchymal stem cells (MSCs), amniotic membrane mesenchymal stem cells (AMSCs), to explore therapeutic effects on Bmi‐1‐deficient caused mandible osteoporosis. Phenotypes of mandibles from 5‐week‐old Bmi‐1‐deficient mice with AMSCs‐based therapy were compared with age‐matched Bmi‐1‐deficient mandibles without AMSCs‐based therapy and wild‐type mice. Bmi‐1‐deficient mice without AMSCs‐based therapy displayed mandible osteoporosis accompanied with the rising senescence‐associated molecules and imbalance redox homeostasis. Results showed that the alveolar bone volume, cortical thickness, type I collagen and osteocalcin immunopositive areas, mRNA expression levels of alkaline phosphatase, superoxide dismutase, gluathione reductase, and protein expression level of Runx2 were all reduced significantly in Bmi‐1−/− mandibles. Protein levels of PPARγ, p16, p21, p53, and redox gene levels of Bnip3l, Cdo1, Duox1, and Duox2 were up‐regulated in mandibles from vehicle‐transplanted Bmi‐1−/− mice. Also, osteoclasts were activated in Bmi‐1−/− alveolar bone. Transplanted AMSCs migrated into mandibles and improved all the parameters in Bmi‐1−/− mandibles with AMSCs‐based therapy. These findings indicate that AMSCs‐based therapy could rescue mandible osteoporosis induced by Bmi‐1 deficiency through stimulating osteoblastic bone formation and inhibiting osteoclastic bone resorption. Our findings implied that AMSCs‐based therapy had preventative and therapeutic potential for mandible osteoporosis.